Powered by

Adlon Therapeutics L.P. and Purdue Pharma L.P. Will Present Data from Adhansia XR(TM) (methylphenidate HCl) Studies Examining Sleep Quality Outcomes, Functional Outcomes and Executive Functioning at the 2020 APSARD Annual Meeting

Jan 16, 2020 - Business Wire

Adlon Therapeutics L.P. and Purdue Pharma L.P. will present data from three studies evaluating PRC-063 at the 2020 American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting in Washington D.C. PRC-063 was approved by the U.S. Food and Drug Administration (FDA) for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients six years and older and is currently available as Adhansia XR(TM) (methylphenidate hydrochloride) extended-release capsules CII.

The Full Prescribing Information for Adhansia XR contains a boxed warning for abuse and dependence. CNS stimulants, including Adhansia XR, other methylphenidate-containing products, and amphetamines have a high potential for abuse and dependence. Healthcare professionals should assess the risk of abuse prior to prescribing Adhansia XR and monitor for signs of abuse and dependence while patients are on therapy...